Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2010;12(6):R92.
doi: 10.1186/bcr2771. Epub 2010 Nov 8.

Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS)

Alastair M Thompson  1 , Lee B Jordan, Philip Quinlan, Elizabeth Anderson, Anthony Skene, John A Dewar, Colin A Purdie; Breast Recurrence in Tissues Study Group
Affiliations
Multicenter Study

Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS)

Alastair M Thompson et al. Breast Cancer Res. 2010.

Abstract

Introduction: Immunohistochemistry of primary breast cancer is routinely used to guide changes in therapy at the time of relapse. Retrospective reviews suggest that the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor type 2 (HER2) receptor may differ between the primary and loco-regional recurrence or distant metastases. The Breast Recurrence In Tissues Study (BRITS) was a large, multicentre, prospective study to examine changes in ER, PR and HER2.

Methods: Matched primary and recurrent breast cancer tissue samples were prospectively collected from 205 women attending 20 institutions. Central laboratory immunohistochemical analysis of core biopsies and tissue microarrays of ER and PR using the Allred and Quickscore methods and HER2 (confirmed by fluorescence in situ hybridisation (FISH) for HER2 2+) were performed.

Results: From 205 consenting women, 18 (8.8%) did not have recurrent disease on biopsy, 35 were ineligible, 13 had insufficient paired tissue and 2 were excluded for safety reasons. Paired samples from 137 women, mean age 62.6 years (range 27-87 years), 83/137 (60.6%) postmenopausal with a median 92.2 months (range 5-327 months) from primary to recurrence and 88 (64.2%) as locoregional recurrence were successfully analysed. A switch in receptor status, in either direction, by Allred score, was identified for ER in 14 patients (10.2%; P = 0.983 Wilcoxon sign rank test), PR in 34 (24.8%; P = 0.003 Wilcoxon sign rank test) and HER2 in 4 (2.9%; P = 0.074 Wilcoxon sign rank test). There was no difference between locoregional or distant recurrence in the proportion who switched. The switch in receptor status led to a change in the subsequent treatment plan for 24 patients (17.5%).

Conclusions: This prospective study confirms retrospective evidence that the management of relapsed breast cancer should include confirmatory tissue sampling and identify switches of ER, PR or HER2 which change therapeutic management for one in six patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Consort diagram of the Breast Recurrence In Tissues Study (BRITS).
See this image and copyright information in PMC

References

    1. Stebbing J, Slater S, Slevin M. Breast cancer (metastatic) Clin Evid (Online) 2007;pii:0811. - PMC - PubMed
    1. Dawood S, Broglio K, Gonzalez-Angulo AM, Buzdar AU, Hortobagyi GN, Giordano SH. Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J Clin Oncol. 2008;26:4891–4898. doi: 10.1200/JCO.2007.14.1168. - DOI - PMC - PubMed
    1. Amir E, Clemons M. Should a biopsy be recommended to confirm metastatic disease in women with breast cancer? Lancet Oncol. 2009;10:933–935. doi: 10.1016/S1470-2045(09)70295-5. - DOI - PubMed
    1. Sharma A, Crook T, Thompson A, Palmieri C. Surgical oncology: why biopsying metastatic breast cancer should be routine. Nat Rev Clin Oncol. 2010;7:72–74. doi: 10.1038/nrclinonc.2009.222. - DOI - PubMed
    1. Brennan MJ, Donegan WL, Appleby DE. The variability of estrogen receptors in metastatic breast cancer. Am J Surg. 1979;137:260–262. doi: 10.1016/0002-9610(79)90159-4. - DOI - PubMed

Publication types

MeSH terms